I. Satia (Hamilton (ON), Canada), C. Porsbjerg (Copenhagen, Denmark), A. Licari (Pavia (PV), Italy), A. Mansur (Birmingham (West Midlands), United Kingdom)
Prevalence of adrenal insufficiency in patients started on Mepolizumab for severe eosinophilic asthma.
G. Tavernier (Manchester, United Kingdom), L. Elsey (Manchester, United Kingdom), N. Bhola (Manchester, United Kingdom), L. Holmes (Manchester, United Kingdom), D. Allen (Manchester, United Kingdom), R. Niven (Manchester, United Kingdom)
|   |
Evaluation of the steroid sparing effects of Mepolizumab using the Glucocorticoid Toxicity Index
P. McDowell (Belfast, United Kingdom), J. Stone (Boston, United States of America), K. Honeyford (Belfast, United Kingdom), L. Dunn (Belfast, United Kingdom), R. Logan (Belfast, United Kingdom), C. Butler (Belfast, United Kingdom), L. Heaney (Belfast, United Kingdom)
| |
Analysis of two-year treatment with omalizumab patients with severe asthma in real clinical practice
E. Blinova (Chelyabinsk, Russian Federation), G. Ignatova (Chelyabinsk, Russian Federation)
| |
Treatment eligibility of mepolizumab-treated severe asthma patients in clinical practice
L. Richards (Amsterdam, Netherlands), J. Van Bragt (Amsterdam, Netherlands), R. Aarab (Amsterdam, Netherlands), J. Sont (Leiden, Netherlands), E. Weersink (Amsterdam, Netherlands), G. Braunstahl (Rotterdam, Netherlands), A. Ten Brinke (Leeuwarden, Netherlands), E. Bel (Amsterdam, Netherlands), A. Maitland-Van Der Zee (Amsterdam, Netherlands)
| |
Real-life treatment of severe eosinophilic asthma with mepolizumab
C. Pelaia (Catanzaro, Italy), M. Busceti (Catanzaro, Italy), S. Solinas (Catanzaro, Italy), R. Terracciano (Catanzaro, Italy), G. Pelaia (Catanzaro, Italy)
| |
Real-world effectiveness of reslizumab for severe eosinophilic asthma (SEA)
A. Subramaniam (Dublin, Ireland), E. Mulligan (Dublin, Ireland), S. Lane (Dublin, Ireland)
| |
Mepolizumab self-administration via autoinjector and prefilled syringe: the qualitative patient experience
L. Evitt (Brentford, United Kingdom), R. Follows (Uxbridge, United Kingdom), W. Williams (Collegeville, United States of America), H. Shalhoub (Bethesda, United States of America), M. Celone (Bethesda, United States of America), S. Yang (Collegeville, United States of America), R. Von Maltzahn (Brentford, United Kingdom)
| |
Safety of Mepolizumab for severe eosinophilic refractory asthma in a single-center cohort including a patient with echinococcus hepatic cyst and a patient with lung cancer . A single center one year follow up.
C. Barbetta (Pordenone, Italy), M. Conte (Pordenone, Italy), F. Zampieri (Pordenone, Italy), C. Rinaldo (Pordenone, Italy), P. Peditto (Pordenone, Italy), M. Tamburrini (Pordenone, Italy), U. Zuccon (Pordenone, Italy), A. Scarda (Pordenone, Italy), C. Baghiris (Pordenone, Italy), F. Buzzulini (Pordenone, Italy), D. Villalta (Pordenone, Italy), F. Mazza (Pordenone, Italy)
| |
Experience with Mepolizumab in a cohort of patients with eosinophilic severe persistent asthma
M. Erro Iribarren (Madrid, Spain), C. Cisneros Serrano (Madrid, Spain), C. Acosta Gutiérrez (Madrid, Spain), A. Roca Noval (Madrid, Spain), A. Martínez Meca (Madrid, Spain), E. García Castillo (Madrid, Spain), M. Hernández Olivo (Madrid, Spain), J. B Soriano (Madrid, Spain), J. Ancochea Bermúdez (Madrid, Spain)
| |
Omalizumab in severe asthma: real life study
M. Costa e Silva (Vila Nova de Gaia, Portugal), I. Sucena (Vila Nova de Gaia, Portugal), I. Ladeira (Vila Nova de Gaia, Portugal), I. Franco (Vila Nova de Gaia, Portugal), I. Pascoal (Vila Nova de Gaia, Portugal), A. Carvalho (Vila Nova de Gaia, Portugal), R. Lima (Vila Nova de Gaia, Portugal)
| |
Self-administration of mepolizumab via an autoinjector: the patient experience
L. Evitt (London, United Kingdom), R. Follows (London, United Kingdom), J. Bentley (London, United Kingdom), W. Williams (Philadelphia, United States of America), R. Von Maltzahn (London, United Kingdom)
| |
Efficacy and safety of Mepolizumab in a real world severe asthma cohort.
v. Mitchell (Birmingham, United Kingdom), K. Howles (Birmingham, United Kingdom), L. White (Birmingham, United Kingdom), A. Pillai (Birmingham, United Kingdom), A. Mansur (Birmingham, United Kingdom)
| |
Real life experience with omalizumab and mepolizumab in severe asthma : do patient baseline features preclude effectiveness comparison ?
A. Frix (Liège, Belgium), F. Schleich (Liège, Belgium), V. Paulus (Liège, Belgium), M. Henket (Liège, Belgium), F. Guissard (Liège, Belgium), R. Louis (Liège, Belgium)
| |
Adherence to omalizumab: a “real-life” study
R. Campisi (Catania, Italy), C. Crimi (Catania, Italy), A. Noto (Messina, Italy), M. Foschino (Foggia, Italy), G. Valenti (Palermo, Italy), V. Viviano (Palermo, Italy), C. Pelaia (Catanzaro, Italy), L. Ricciardi (Messina, Italy), N. Scichilone (Palermo, Italy), N. Crimi (Catania, Italy)
| |
Does adherence to ICS/LABA therapy affect response to mepolizumab in the treatment of severe asthma?
G. d'Ancona (London, United Kingdom), L. Green (London, United Kingdom), M. Fernandes (London, United Kingdom), C. Roxas (London, United Kingdom), L. Osman (London, United Kingdom), K. Stewart-Knight (London, United Kingdom), J. Kavanagh (London, United Kingdom), A. Nanzer-Kelly (London, United Kingdom), D. Jackson (London, United Kingdom), B. Kent (London, United Kingdom)
| |
Real-world oral glucocorticoid-sparing effect of benralizumab in severe asthma
D. Jackson (London, United Kingdom), C. Roxas (London, United Kingdom), L. Thompson (London, United Kingdom), M. Fernandes (London, United Kingdom), L. Green (London, United Kingdom), J. Kavanagh (London, United Kingdom), A. Nanzer-Kelly (London, United Kingdom), G. D'Ancona (London, United Kingdom), B. Kent (London, United Kingdom)
| |
Mepolizumab efficacy in patients with severe eosinophilic asthma and bronchiectasis
C. Crimi (Catania, Italy), R. Campisi (Catania, Italy), G. Cacopardo (Catania, Italy), G. Doria (Catania, Italy), R. Intravaia (Catania, Italy), P. Morena (Catania, Italy), G. Sabrina (Catania, Italy), R. Sorrentino (Catania, Italy), N. Crimi (Catania, Italy)
| |
Evaluation of bronchial hyperreactivity and other functional parameters in severe asthma patients treated with anti-interleukin-5 monoclonal antibody (IL5)
F. Bini (Garbagnate milanese, Italy), N. Grassi (Garbagnate milanese, Italy), D. Visca (Tradate, Italy), A. De Lauretis (Garbagnate milanese, Italy), A. Spanevello (Tradate, Italy), A. Vaghi (Garbagnate milanese, Italy)
| |
A single-center observational study assessing response to mepolizumab in severe eosinophilic asthma
N. Tan (S, Singapore), M. Mukherjee (Toronto, Canada), S. Lim (Singapore, Singapore), C. Thiam (Singapore, Singapore), W. Tan (Singapore, Singapore), W. Wong (Singapore, Singapore), P. Nair (Toronto, Canada), V. Angeli (Singapore, Singapore), H. Lim (Singapore, Singapore)
| |
Discontinuation rates of omalizumab treatment in a cohort of severe asthmatics in Bulgaria
D. Hristova (Sofia, Bulgaria), T. Kralimarkova (Sofia, Bulgaria), T. A Popov (Sofia, Bulgaria)
| |